Bamlanivimab
Bamlanivimab is a pharmaceutical drug with 8 clinical trials. Historical success rate of 80.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
3
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
80.0%
4 of 5 finished
20.0%
1 ended early
0
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2
Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting
At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19
Clinical Trials (8)
COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2
Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting
At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff
A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8